西达本胺联合林普利塞治疗复发性血管免疫母细胞性T细胞淋巴瘤1例并文献复习  

Chidamide combined with linperlisib in treatment of recurrent angioimmunoblastic T-cell lymphoma:report of 1 case and review of literature

作　　者：宋远斌 许静霞 王韵[1] 梁洋 吴秉毅 Song Yuanbin;Xu Jingxia;Wang Yun;Liang Yang;Wu Bingyi(Department of Hematology,Sun Yat-Sen University Cancer Center,Guangzhou 510555,China)

机构地区：[1]中山大学肿瘤防治中心,广州510555

出　　处：《白血病．淋巴瘤》2024年第10期622-625,共4页Journal of Leukemia & Lymphoma

摘　　要：目的探讨西达本胺联合林普利塞治疗自体造血干细胞移植(ASCT)后复发血管免疫母细胞性T细胞淋巴瘤(AITL)的临床效果。方法回顾性分析中山大学肿瘤防治中心2021年3月收治的1例采用西达本胺联合林普利塞治疗的ASCT后复发AITL患者的临床资料,并复习相关文献。结果患者,男性,55岁,因乏力、盗汗、消瘦就诊,完善淋巴结活组织病理诊断为AITL。给予维布妥昔单抗联合CDP方案达完全缓解后行ASCT,移植后采用程序性死亡受体1抑制剂维持;移植16个月后复发,复发后应用西达本胺联合林普利塞1个疗程后达部分缓解,2个疗程后达完全缓解。后因自行停用抗乙型肝炎药物,复查乙型肝炎病毒定量升高,暂停原发病治疗随访截至2024年3月,复查全身增强磁共振成像提示复发。结论西达本胺联合林普利塞治疗ASCT后复发ATIL近期效果良好,安全有效。Objective To investigate the clinical effects of chidamide combined with linperlisib in treatment of recurrent angioimmunoblastic T-cell lymphoma(AITL)after autologous stem cell transplantation(ASCT).Methods The clinical data of 1 patient with recurrent AITL receiving treatment of chidamide combined with linperlisib after ASCT in Sun Yat-Sen University Cancer Center in March,2021 were retrospectively analyzed,and the related literatures were reviewed.Results The 55-year-old male patient was presented with fatigue,night sweats and emaciation.According to the results of pathology,immunohistochemistry and imaging after admission,this patient was diagnosed as AITL.After treatment with venbutuximab+CDP(cyclophosphamide+doxorubicin+prednisone)regimen,the patient achieved complete remission,and then ASCT was performed.After the transplatation,programmed death receptor 1 inhibitor was maintained for 4 courses of treatment.It recurred 16 months after ASCT,and the patient achieved partial remission after 1 course of chidamide combined with linperlisib,and achieved complete remission after 2 courses of treatment.Later,recheck of hepatitis B virus showed a quantitative increase after the self withdrawal of anti hepatitis B drugs,and then the primary treatment was suspended.The last follow-up time was March,2024,and recheck results of whole body enhanced magnetic resonance imaging indicated recurrence.Conclusions The combination of chidamide and linperlisib is effective and safe in treatment of recurrent ATIL after ASCT.

关 键 词：免疫母细胞淋巴结病 复发 组蛋白脱乙酰基酶抑制剂 磷脂酰肌醇-3-激酶 

分 类 号：R732.2[医药卫生—肿瘤]